Last reviewed · How we verify

NCT00684853

Intravitreal Bevacizumab Combined With PDT (Full Fluence) Versus Bevacizumab to Treat Exudative Age-Related Macular Degeneration

Status unknown Phase 2 Last updated 27 May 2008
What this trial tests

Phase 2 trial testing bevacizumab in Macular Degeneration in 50 participants. Status unknown.

Timeline
1 November 2007
Primary endpoint
1 May 2008

Quick facts

Lead sponsorFederal University of São Paulo
PhasePhase 2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment50
Start date1 November 2007
Primary completion1 May 2008
Sites1 location across Brazil

Drugs / interventions tested

Conditions studied

Sponsor

Federal University of São Paulo

Who can join

50 and older, any sex, with Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to determine the association of bevacizumab and PDT is safety and effective in the treatment of exudative AMD

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of bevacizumab

Trials testing the same drug.

Other recruiting trials for Macular Degeneration

Currently open trials in the same condition.

Other Federal University of São Paulo trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00684853.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing